Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity - PubMed (original) (raw)

Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity

V Rasolofo-Razanamparany et al. Infect Immun. 2001 Sep.

Abstract

The mucosal humoral immune response elicited following Shigella flexneri infection in patients living in Antananarivo districts (Madagascar Island) was evaluated by measuring the gut-derived, circulating immunoglobulin A (IgA) antibody-secreting cells (ASC) specific for the major bacterial antigen lipopolysaccharide (LPS). Fifty, 34, 11, and 5% of the S. flexneri-positive patients were infected with serotypes 2a, 1a, 4a, and 3a, respectively. The total number of IgA ASC in infected patients increased significantly, compared to the number in healthy controls, early after the onset of disease. The number of anti-homologous LPS IgA ASC varied among individuals and peaked between days 5 and 10 after the onset of the disease. In the S. flexneri 1a- and 2a-infected patients, the level of IgA ASC cross-reactivity to heterologous S. flexneri serotypes was weak. These data indicate that S. flexneri 2a and 1a are the predominant strains responsible for shigellosis in this area of endemicity and that the anti-LPS antibody response following natural infection is mainly directed against serotype-specific determinants.

PubMed Disclaimer

Figures

FIG. 1

FIG. 1

(A) Anti-homologous LPS IgA ASC response in S. flexneri 1a-, 2a-, and 4a-infected patients. Mean values and standard errors are represented for each patient at each time point. (B) Anti-heterologous LPS IgA ASC response in S. flexneri 1a- and 2a-infected patients. Cross-reactivity for serotypes 2a, 3a, and 4a and 1a, 3a, and 4a was evaluated at the peak of the response for each of the S. flexneri 1a- and 2a-infected patients, respectively. It is expressed as the percentage of IgA ASC recognizing heterologous LPS among the anti-homologous LPS IgA ASC.

References

    1. Cassel-Béraud A M, Coulanges P, Richard C. Evolution des résistances aux antibiotiques des souches de Shigella dysenteriae type 1 (bacilles de Shiga) isolées à Tananarive et sur la côte Est de Madagascar. Arch Inst Pasteur Madagascar. 1989;56:71–76. -PubMed
    1. Cohen D, Ashkenazi S, Green M S, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet. 1997;349:155–159. -PubMed
    1. Coster T S, Hoge C W, VanDeVerg L L, Hartman A B, Oaks E V, Venkatesan M M, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti P J, Hale T L. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun. 1999;67:3437–3443. -PMC -PubMed
    1. Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol. 1996;44:217–224. -PubMed
    1. Kantele A M, Takanen R, Arvilommi H. Immune response to acute diarrhea seen as circulating antibody-secreting cells. J Infect Dis. 1988;158:1011–1015. -PubMed

MeSH terms

Substances

LinkOut - more resources